Allergan PLC has returned the global development and sales rights of evogliptin as a non-alcoholic steatohepatitis (NASH) therapy to Dong-A ST Co. Ltd. as of Nov. 1, ending a 2016 licensing agreement for the DPP-4 inhibitor.
[Sidebar#SC089424]
With Allergan handing back the global development and sales rights of evogliptin as a NASH therapy to Dong-A, the South Korean firm is now considering an alternative business model around the DPP-4 inhibitor.

Allergan PLC has returned the global development and sales rights of evogliptin as a non-alcoholic steatohepatitis (NASH) therapy to Dong-A ST Co. Ltd. as of Nov. 1, ending a 2016 licensing agreement for the DPP-4 inhibitor.
[Sidebar#SC089424]
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.